Novo Integrated Sciences Inc (NVOS)

[gail]

or not, lol. but its trying.

[gail]

this wants to move, im holding.

[gail]

shelly from admin fixed it.

[gail]

i wish ihub’s chart and…

….

L2 would update.

i will let admin know, they were able to fix one, that went to the otc before, that didnt update.

[TrendTrade2016]

NVOS HERE WE GO

[gail]

moving up now.

[TrendTrade2016]

NVOS NASDAQ TO OTC PLAY

[gail]

grabbed some today. hi all.

[Renee]

NVOS delisted from the Nasdaq to the OTC:

https://otce.finra.org/otce/dailyList?viewType=Additions

[georgie18]

NVOS...23s clearing here...Off my .22 Alert...🥳

georgie18

Member Level
Re: None

Monday, October 21, 2024 10:30:26 AM

Post#
6658
of 6661
NVOS...22...Scaling in here...🥳

[marianothis]

Ok, ty

[georgie18]

Oversold chart play sitting at the lower Keltner Line…🥳

[marianothis]

why ?

[georgie18]

NVOS...22...Scaling in here...🥳

[Monksdream]

NVOS new 52 week low

[Monksdream]

NVOS new 52 low

[Gone Postal]

And another one bites the dust. 💩

[mgland]

NVOS delisted 8K AH.
Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing


https://www.sec.gov/ix?doc=/Archives/edgar/data/1138978/000149315224032650/form8-k.htm


On February 9, 2024, Novo Integrated Sciences, Inc. (the “Company”) received a letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, based upon the closing bid price of the Company’s common stock, par value $0.001 per share (“Common Stock”), for the last 30 consecutive business days, the Company was not in compliance with the requirement to maintain a minimum bid price of $1.00 per share (the “Minimum Bid Price Requirement”) for continued listing on The Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550(a)(2) (the “Original Notice”). At that time, the Company was provided a compliance period of 180 calendar days from the date of the Original Notice, or until August 7, 2024, to regain compliance with the Minimum Bid Price Requirement, pursuant to Nasdaq Listing Rule 5810(c)(3)(A).



As the Company did not regain compliance with the Minimum Bid Price Requirement by August 7, 2024, and it was determined by the Nasdaq Staff that the Company should not be eligible for another 180 calendar-day extension, the Company received a delisting determination letter on August 9, 2024. Accordingly, the Company intends to timely request a hearing before a Nasdaq Hearing Panel (“Panel”). The hearing request will automatically stay any suspension or delisting action pending the hearing and the expiration of any additional extension period granted by the Panel following the hearing. In that regard, pursuant to the Nasdaq Listing Rules, the Panel has the discretion to grant the Company an additional extension period not to exceed February 5, 2025. However, there can be no assurance that the Panel will grant the Company an additional extension period or that the Company will ultimately meet all applicable requirements for continued listing on The Nasdaq Capital Market. The Company intends to provide a plan to regain compliance to the Panel.

[glenn1919]

NVOS..................................https://stockcharts.com/h-sc/ui?s=NVOS&p=W&b=5&g=0&id=p86431144783

[subslover]

Novo Integrated Sciences Receives Commencement of Disbursement Notice for SBLC Leasing and Monetizing Program
BELLEVUE, Wash.--(BUSINESS WIRE)-- Novo Integrated Sciences, Inc. (NASDAQ: NVOS) (the “Company” or “Novo”) announced today that it has received notice of the commencement of disbursement for the complete monetization of a Standby Letter of Credit (“SBLC”). The initial disbursement represents the first payment as per the arrangement creating a release of lien resulting in the subsequent final advance to the Company. With this initial disbursement the Company expects final distribution to follow on or before August 2. As previously reported, the Company entered into an application for the monetizing program whereby the Company is projected to receive gross funding proceeds of approximately $78 million under the SBLC monetization program.

Robert Mattacchione, Novo’s CEO and Board Chairman, stated, "The commencement of distribution marks the first payments in the process of full monetization of the SBLC. This step will now lead us to receiving our full expected payout as identified in the transaction documents. We look forward to engaging in our intended initiatives.”

About Novo Integrated Sciences, Inc.

Novo Integrated Sciences, Inc. is pioneering a holistic approach to patient-first health and wellness through a multidisciplinary healthcare ecosystem of services and product innovation. Novo offers an essential and differentiated solution to deliver, or intend to deliver, these services and products through the integration of medical technology, advanced therapeutics, and rehabilitative science.

We believe that “decentralizing” healthcare, through the integration of medical technology and interconnectivity, is an essential solution to the rapidly evolving fundamental transformation of how non-catastrophic healthcare is delivered both now and in the future. Specific to non-critical care, ongoing advancements in both medical technology and inter-connectivity are allowing for a shift of the patient/practitioner relationship to the patient’s home and away from on-site visits to primary medical centers with mass-services. This acceleration of “ease-of-access” in the patient/practitioner interaction for non-critical care diagnosis and subsequent treatment minimizes the degradation of non-critical health conditions to critical conditions as well as allowing for more cost-effective healthcare distribution.

The Company’s decentralized healthcare business model is centered on three primary pillars to best support the transformation of non-catastrophic healthcare delivery to patients and consumers:

First Pillar: Service Networks. Deliver multidisciplinary primary care services through (i) an affiliate network of clinic facilities, (ii) small and micro footprint sized clinic facilities primarily located within the footprint of box-store commercial enterprises, (iii) clinic facilities operated through a franchise relationship with the Company, and (iv) corporate operated clinic facilities.
Second Pillar: Technology. Develop, deploy, and integrate sophisticated interconnected technology, interfacing the patient to the healthcare practitioner thus expanding the reach and availability of the Company’s services, beyond the traditional clinic location, to geographic areas not readily providing advanced, peripheral based healthcare services, including the patient’s home.
Third Pillar: Products. Develop and distribute effective, personalized health and wellness product solutions allowing for the customization of patient preventative care remedies and ultimately a healthier population. The Company’s science-first approach to product innovation further emphasizes our mandate to create and provide over-the-counter preventative and maintenance care solutions.
Innovation through science combined with the integration of sophisticated, secure technology assures Novo Integrated Sciences of continued cutting-edge advancement in patient-first platforms.

For more information concerning Novo Integrated Sciences, please visit www.novointegrated.com.

Twitter, LinkedIn, Facebook, Instagram, YouTube

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, or the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts included in this press release are forward-looking statements. In some cases, forward-looking statements can be identified by words such as "believe," “intend,” "expect," "anticipate," "plan," "potential," "continue," or similar expressions. Such forward-looking statements include risks and uncertainties, and there are important factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These factors, risks, and uncertainties are discussed in Novo’s filings with the Securities and Exchange Commission. Investors should not place any undue reliance on forward-looking statements since they involve known and unknown uncertainties and other factors which are, in some cases, beyond Novo’s control which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects Novo’s current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to operations, results of operations, growth strategy and liquidity. Novo assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. The contents of any website referenced in this press release are not incorporated by reference herein.

https://cts.businesswire.com/ct/CT?id=bwnews&sty=20240718621664r1&sid=acqr8&distro=nx&lang=en
View source version on businesswire.com: https://www.businesswire.com/news/home/20240718621664/en/

Chris David, COO
Novo Integrated Sciences, Inc.
[e-mail]
[phone]

Source: Novo Integrated Sciences, Inc.

© Copyright Business Wire 2024
Back to News Headlines
Other Financial Information

[Dr PennyStock]

$NVOS on fire after-hours. It's trading now at .81, and already made a HOD at .89.
This is what caused the run: https://finance.yahoo.com/news/novo-integrated-sciences-receives-commencement-200500031.htm

[marianothis]

sounds good to me.

[Dr PennyStock]

Strong close. Tomorrow should be a good day.

[marianothis]

longs are ready.....

[Dr PennyStock]

$NVOS made a higher low and a higher high, breaking the resistance at .575. The run to fill the gap at .733 is imminent. Then the run to $5 - $5.38 will initiate.

Weekly chart: https://schrts.co/KWnVIpPq

[georgie18]

NVOS...56...Trading sideways...seems to building a base in this range...off the .45 range dip...Open Gap in the .75 range...🥳

[Sibware]

NVOS:So-close to-push hourly top-bolly at 0.57 b4-effectiveness

[georgie18]

NVOS...55s hitting here in the P/M...Off the .45 range dip...🥳

[georgie18]

NVOS...5199...Bullish Harami forming here off the .45 range dip...🥳

[georgie18]

Thanks Sib...🥳

[Sibware]

NVOS: Nice grab on this DB. Noteholder should push the top bollies on all counts b4 effectiveness and next PR
Happy to see you healthy like a 10 bagger chart in progress

[georgie18]

NVOS...50...Nice bids stacking here...🥳

[georgie18]

NVOS...4966 after the .45 range dip...🥳

georgie18

Member Level
Re: georgie18 post# 647672

Tuesday, July 09, 2024 3:30:48 PM

Post#
649307
of 649374
NVOS...45...Hit my target...🥳

georgie18

Member Level
Re: None

Thursday, June 20, 2024 10:59:43 AM

Post#
381519
of 381773
NVOS...78...Watching to see if it fills that .45 range gap...No position...🥳

[Sibware]

NVOS: Bought back today on this nice DB near 0.45ishes after yesterday's S-1

[Dr PennyStock]

How Outstanding Shares Work

As noted above, a company's outstanding shares are those that are held by its shareholders. Any authorized shares that are held by or sold to a corporation’s shareholders, exclusive of treasury stock which is held by the company itself, are known as outstanding shares.

Source: https://www.investopedia.com/terms/o/outstandingshares.asp

The Outstanding shares represent 100 pct of the company at all times.

How can the OS represent 100% of the company if it does not include the treasury stock? So lets say that a company bought back 20% of the issued and outstanding shares, and these shares are now in the treasury. How can the OS represent 100% of the company at all times? In this case represent only 80%.

But suppose that the company bought back 80% of the OS. In this case the OS will represent only 20% of the company, or not?

[valleybenedetto]

The Outstanding shares represent 100 pct of the company at all times. AS is max they can issue to represent that 100pct hence when the OS goes UP your %ownership in the company goes DOWN..

[georgie18]

NVOS...48s clearing here...🥳off the 44 dip...

[Dr PennyStock]

I have a theory about this sell-off.

This sell-off is very advantageous for the company, because at this price, with the $10M they said they were going to use in the stock buyback, they can buy the entire OS.

$10,000,000 : .50 = 20,000,000

They could avoid the sell-off if today before the market opened they put out a press release saying they were going to start the buyback.

But they didn't, and I think deliberately.

If I am right, this can make a bigger and faster run than I was expecting, even if this sell-off looks ugly.

[Dr PennyStock]

An example.

I own a private company and decide to sell 25% of the company on the stock exchange. To make the calculation easier, let's say that 25% of the company is 25 shares.

These shares are issued and sold on the stock exchange. For example, you buy the 25 shares, and by buying the 25 shares (all the shares issued and outstanding), you buy 100% of the company, is that it?

The OS represents 100 pct of the currently issued shares

. Yes, but not 100% of the company, right?

[valleybenedetto]

🫡

[marianothis]

thank you....

[valleybenedetto]

No that is absolutely incorrect. The OS represents 100 pct of the currently issued shares. 3.5 million equates to 17.7775 pct dilution to current shareholders.

[Dr PennyStock]

I think the AS is more adequate. The AS is 499M, the OS is 19M, so the OS represents 100% of the company?

[valleybenedetto]

What else do you use ?

[Dr PennyStock]

So you use the OS to do that!? Nice

[valleybenedetto]

17.775 percent to be exact
20m OS
3.5m added do the math.

[Dr PennyStock]

More or less 0.7%, not 18%.

[valleybenedetto]

Thats 18 percent of the company.

[Sibware]

Last S1 is only for 3.5 million too...

[marianothis]

Good news, thank you